Treosulfan
Trecondi (treosulfan) is a small molecule pharmaceutical. Treosulfan was first approved as Trecondi on 2019-06-20. It has been approved in Europe to treat hematopoietic stem cell transplantation.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 2 | 13 | 1 | — | — | 15 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 10 | 1 | — | — | 12 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 5 | 3 | — | — | 7 | |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | 1 | — | — | 1 | |
| Melanoma | D008545 | — | — | 1 | — | — | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | 2 | 4 | — | — | — | 5 | ||
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 4 | — | — | — | 4 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | — | 4 | — | — | — | 4 | |
| Multiple myeloma | D009101 | C90.0 | 2 | 3 | — | — | — | 4 | |
| Leukemia | D007938 | C95 | 2 | 3 | — | — | — | 4 | |
| Hodgkin disease | D006689 | C81 | — | 3 | — | — | — | 3 | |
| Graft vs host disease | D006086 | D89.81 | 1 | 2 | — | — | — | 3 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 2 | — | — | — | 2 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 2 | — | — | — | 2 | |
| Bone marrow failure disorders | D000080983 | — | 2 | — | — | — | 2 |
Show 23 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TREOSULFAN |
| INN | treosulfan |
| Description | Treosulfan is a methanesulfonate ester. |
| Classification | Small molecule |
| Drug class | antineoplastics, alkylating agents (methane sulfonate derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 299-75-2 |
| RxCUI | 38508 |
| ChEMBL ID | CHEMBL455186 |
| ChEBI ID | 82557 |
| PubChem CID | 9882105 |
| DrugBank | DB11678 |
| UNII ID | CO61ER3EPI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,354 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,927 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more